<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00707850</url>
  </required_header>
  <id_info>
    <org_study_id>BRCGL-08-06</org_study_id>
    <nct_id>NCT00707850</nct_id>
  </id_info>
  <brief_title>Pegasys® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus Infection</brief_title>
  <official_title>A Study on PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin) in Iranian Thalassemic Patients With Chronic Hepatitis C Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baqiyatallah Medical Sciences University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baqiyatallah Research Center for Gastroenterology and Liver Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tehran Hepatitis Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guilan Research Center for Gastroenterology and Liver Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tabriz Research Center for Gastroenterology and Liver Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baqiyatallah Medical Sciences University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antiviral treatment of HCV in thalassemia has raised concerns of ribavirin-induced hemolysis
      and increased iron loading. Blood Transfusion in Thalassemic patients are a known high risk
      for acquiring hepatitis C. The investigators are trying the PEGASYS (Peginterferon
      alpha-2a(40 KD)) plus Ribavirin in Thalassemic patients with HCV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with Thalassemia receive chronic blood transfusions and have an increased prevalence
      of chronic Hepatitis C virus (HCV) infection, particularly if transfused before HCV
      serological testing became available. The investigators enrolled 300 patients into the study.
      The patients received PEGASYS (Peginterferon alpha-2a(40 KD)) 180 microgram per week plus
      COPEGUS (Ribavirin) 1000 milligram for weight less than or equal 75 kg and 1200 milligram for
      more than 75 kg for 48 weeks. Follow up period is 6 months after treatment. The patients are
      visited every 4 weeks with biochemistry lab tests. The patients are checked with quantitative
      HCV RNA (Ribonucleic Acid) on the third months after initiation of the treatment to assess
      early virologic response and at the end of the study for complete response rate and on the
      six month after treatment completion for sustained response rate. The patients with
      undetectable HCV RNA are considered as responders.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early Virologic Response</measure>
    <time_frame>After 12 weeks of Treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>End of Treatment Response</measure>
    <time_frame>48 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sustained Virologic Response</measure>
    <time_frame>24 weeks after Treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rapid Virologic Response</measure>
    <time_frame>One month after Treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability of drugs for whole therapy period</measure>
    <time_frame>During Treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical response (ALT)</measure>
    <time_frame>End of Treatment AND 24 weeks after Treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Parameters</measure>
    <time_frame>During Treatment AND End of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Thalassemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thalassemic Patients with HCV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)</intervention_name>
    <description>PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: [=&lt;75 kg: 1000 mg; &gt;75 kg: 1200 mg per day (PO)]</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Peginterferon Alfa-2a (40KD) plus COPEGUS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HCV RNA positive

          -  Age older than 12 years

        Exclusion Criteria:

          -  Ongoing pregnancy or breast feeding

          -  History (Hx) of Hepatocellular Carcinoma (HCC)

          -  Hx of alcoholic liver disease

          -  Hx of bleeding from esophageal varices

          -  Hx of hemochromatosis

          -  Hx of autoimmune hepatitis

          -  Hx of Suicidal attempt

          -  Hx of cerebrovascular dis

          -  Hx of severe retinopathy

          -  Hx of severe psoriasis

          -  Hx of scleroderma

          -  Hx of metabolic liver disease

          -  Hx of Systemic Lupus Erythematosus (SLE)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seyed-Moayed Alavian, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Baqiyatallah Research Center for Gastroenterology and Liver Disea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seyyed Mohammad Miri, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Baqiyatallah Research Center for Gastroenterology and Liver Disea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pegah Karimi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baqiyatallah Research Center for Gastroenterology and Liver Diseases</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maryam Keshvari, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Iranian blood Transfusion Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bita Behnava, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baqiyatallah Research Center for Gastroenterology and Liver Diseases</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammad Hossein Somi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Center for Gastroenterology and Hepatology, Tabriz University of Medical Sciences, Tabriz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fariborz Mansour-Ghanaei, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gastroenterology and Liver Diseases, Gastrointestinal and Liver Diseases Research Center (GLDRC), Guilan University of Medical Sciences, Rasht, Iran</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baqiyatallah Research Center for Gastroenterology and Liver Diseases</name>
      <address>
        <city>Tehran</city>
        <zip>14155-3651</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <link>
    <url>http://brcgl.com/</url>
    <description>Baqiyatallah Research Center for Gastroenterology and Liver Diseases</description>
  </link>
  <reference>
    <citation>Harmatz P, Jonas MM, Kwiatkowski JL, Wright EC, Fischer R, Vichinsky E, Giardina PJ, Neufeld EJ, Porter J, Olivieri N; Thalassemia Clinical Research Network. Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. Haematologica. 2008 Aug;93(8):1247-51. doi: 10.3324/haematol.12352. Epub 2008 Jun 12.</citation>
    <PMID>18556414</PMID>
  </reference>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2008</study_first_submitted>
  <study_first_submitted_qc>June 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2008</study_first_posted>
  <last_update_submitted>August 30, 2010</last_update_submitted>
  <last_update_submitted_qc>August 30, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2010</last_update_posted>
  <responsible_party>
    <name_title>Professor Seyed-Moayed Alavian</name_title>
    <organization>Baqiyatallah Research Center for Gastroenterology and Liver Diseases</organization>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>Thalassemia</keyword>
  <keyword>Pegasys</keyword>
  <keyword>Ribavirin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

